BiotechTube

SHR7280

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Sensitive Prostate Cancer

Conditions

Hormone Sensitive Prostate Cancer

Trial Timeline

Sep 24, 2021 → May 25, 2023

NCT ID
NCT04995042

About SHR7280

SHR7280 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hormone Sensitive Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04995042. Target conditions include Hormone Sensitive Prostate Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Hormone Sensitive Prostate Cancer were approved

Approved (9) Terminated (2) Active (11)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04995042Phase 1Completed

Competing Products

20 competing products in Hormone Sensitive Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
44
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
YM598Astellas PharmaPhase 2
27
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
35
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
50
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29